{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:42:58Z","timestamp":1792798978609,"version":"4.5.0"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Samsung Bioepis","id":[{"id":"https:\/\/ror.org\/02a6d4p26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2023,11,22]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of SB15 versus reference aflibercept (AFL), and switching from AFL to SB15 in neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective, double-masked, randomised, phase 3 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with nAMD were randomised 1:1 to receive SB15 (N=224 participants) or AFL (N=225). At week 32, participants either continued on SB15 (SB15\/SB15, N=219) or AFL (AFL\/AFL, N=108), or switched from AFL to SB15 (AFL\/SB15, N=111). This manuscript reports 1-year and switching results of secondary efficacy endpoints such as changes from baseline to week 56 in best-corrected visual acuity (BCVA), central subfield thickness (CST, from internal limiting membrane (ILM) to retinal pigment epithelium), and total retinal thickness (TRT, from ILM to Bruch\u2019s membrane). Additional endpoints included safety, PK and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Efficacy results were comparable between groups. The least squares mean (LSmean) change in BCVA from baseline to week 56 was 7.4 letters for SB15\/SB15 and 7.0 letters for AFL\/AFL (difference (95% CI)=0.4 (\u22122.5 to 3.2)). The LSmean changes from baseline to week 56 in CST and TRT were \u2212119.2 \u00b5m and \u2212132.4 \u00b5m for SB15\/SB15 and \u2212126.6 \u00b5m and \u2212136.3 \u00b5m for AFL\/AFL, respectively (CST: difference (95% CI)=7.4 \u00b5m (\u22126.11 to 20.96); TRT: difference (95% CI)=3.9 \u00b5m (\u221218.35 to 26.10)). Switched and non-switched participants showed similar LSmean changes in BCVA from baseline to week 56 (AFL\/SB15, 7.9 letters vs AFL\/AFL, 7.8 letters; difference (95% CI)=0.0 (\u22122.8 to 2.8)). Safety, PK and immunogenicity were comparable between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Efficacy, safety, PK and immunogenicity were comparable between SB15 and AFL and between switched and non-switched participants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001561","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T19:30:10Z","timestamp":1703014210000},"page":"e001561","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04450329","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R","family":"Sadda","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Doheny Eye Institute, Pasedena, California, USA"},{"name":"Ophthalmology, University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bradvica","sequence":"additional","affiliation":[{"name":"Medical Faculty, Univesity Josip Juraj Strossmayer, Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Vajas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Yeungnam University School of Medicine and College of Medicine, Daegu, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Axon Clinical, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Studni\u010dka","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospital, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Veith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Kralovske Vinohrady, Prague, Czech Republic"},{"name":"Department of Ophthalmology, Charles University Third Faculty of Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-3789","authenticated-orcid":false,"given":"Edward","family":"Wylegala","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[{"name":"Retina Research Institute, Abilene, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolmin","family":"Yun","sequence":"additional","affiliation":[{"name":"Ophthalmology, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-1405","authenticated-orcid":false,"given":"Michal","family":"Orski","sequence":"additional","affiliation":[{"name":"Ophthalmology, Rydygier Memorial Hospital, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Astakhov","sequence":"additional","affiliation":[{"name":"First Pavlov State Medical University, St.Petersburg, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"T\u00f3th-Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Szeged, Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Csutak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, P\u00e9cs University Medical School, P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Enyedi","sequence":"additional","affiliation":[{"name":"Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooree","family":"Choi","sequence":"additional","affiliation":[{"name":"Samsung Bioepis Co., Ltd, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Oh","sequence":"additional","affiliation":[{"name":"Samsung Bioepis Co., Ltd, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyerin","family":"Jang","sequence":"additional","affiliation":[{"name":"Samsung Bioepis Co., Ltd, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-7169","authenticated-orcid":false,"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2025090109253061000_8.1.e001561.1","unstructured":"FDA . Scientific considerations in demonstrating Biosimilarity to a reference product. Available: https:\/\/www.fda.gov\/media\/82647\/download [Accessed 7 Mar 2023]."},{"key":"2025090109253061000_8.1.e001561.2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An introduction to Biosimilars for the treatment of retinal diseases: a narrative review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"2025090109253061000_8.1.e001561.3","unstructured":"Sagong M , Lee H , Huh J , et al . Analytical similarity assessment of an Aflibercept Biosimilar Sb15 to its commercially available reference product (Eylea). 2023 ARVO Annual Meeting 2023; (Abstract Number:); 2023"},{"key":"2025090109253061000_8.1.e001561.4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the Aflibercept Biosimilar Sb15 in Neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2025090109253061000_8.1.e001561.5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.917814","article-title":"Switching among Biosimilars: a review of clinical evidence","volume":"13","author":"Allocati","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025090109253061000_8.1.e001561.6","unstructured":"Medicines for Europe . Positioning statements on physician-led switching for Biosimilar medicines. Available: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2017\/03\/M-Biosimilars-Overview-of-positions-on-physician-led-switching.pdf [Accessed 7 Mar 2023]."},{"key":"2025090109253061000_8.1.e001561.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"2025090109253061000_8.1.e001561.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2025090109253061000_8.1.e001561.9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"2025090109253061000_8.1.e001561.10","unstructured":"EMA . Summary of product characteristics - Eylea. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf [Accessed 7 Mar 2023]."},{"key":"2025090109253061000_8.1.e001561.11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The efficacy, safety, and Immunogenicity of switching between reference biopharmaceuticals and Biosimilars: a systematic review","volume":"108","author":"Barbier","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2025090109253061000_8.1.e001561.12","unstructured":"EMA . Biosimilar medicines can be interchanged. Available: https:\/\/www.ema.europa.eu\/en\/news\/biosimilar-medicines-can-be-interchanged#:~:text=EMA%20and%20the%20Heads%20of,or%20with%20an%20equivalent%20biosimilar [Accessed 7 Mar 2023]."},{"key":"2025090109253061000_8.1.e001561.13","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41433-022-02287-w","article-title":"Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?","volume":"37","author":"Sharma","year":"2023","journal-title":"Eye (Lond)"},{"key":"2025090109253061000_8.1.e001561.14","unstructured":"EMA . Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf [Accessed 7 Mar 2023]."},{"key":"2025090109253061000_8.1.e001561.15","unstructured":"EMA . Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf [Accessed 7 Mar 2023]."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:25:40Z","timestamp":1756743940000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,19]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjophth-2023-001561"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001561","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}